10:33 AM EST - Knight Therapeutics Inc. : Has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. Knight Therapeutics Inc.
shares T.GUD are trading down $0.02 at $4.55.
